Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Obesity is a chronic disease that often requires ongoing management, similar to other chronic diseases like hypertension or diabetes
GLP-1 receptor agonist drugs like Trulicity and Ozempic have proved very effective in managing diabetes and obesity, but because of the way they work, they can present problems when it comes to preparing for a colonoscopy and endoscopy
Market Scope Market Dynamics Drivers Burgeoning demand for potent metabolic therapies The rising cases of type 2 diabetes and obesity in Australia, growing trend of early diagnosis for timely interventions, changing lifestyles and the need for effective treatment strategies to lower the disease burden and improving patient health outcomes are boosting the demand for GLP-1 receptor agonists in Australia
Shang et al[16]
(PubMed) Keith DJ, Butler JA, Bemer B, et al
ZP CON BS 25FEB2026 Zepbound , its delivery device base and KwikPen are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates
